Track topics on Twitter Track topics that are important to you
Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company’s discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections. Achillion’s drug development pipeline is led by elvucitabine (Beta-L-Fd4C or ACH-126,443), which is currently in late-stage Phase 2 clinical trials for the treatment of patients infected with HIV. Achillion’s candidate for the potential treatment of HCV infection, ACH-806, is in a Phase 1 clinical trial and is anticipated to be completed by the first half of 2006.
300 George Street
United States of America
Johnson & Johnson has announced that it is to back out of a $1.1 billion deal with Achillion Pharmaceuticals to develop the firm’s hepatitis C drug pipeline. The news sent Achillion’s stock re...
Achillion Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued a U.S. Patent to Achillion for ACH-4471. U.S. Patent No.
Wall Street brokerages expect Achillion Pharmaceuticals, Inc. to announce earnings per share of for the current quarter, Zacks reports. Zero analysts have provided estimates for Achillion Pharmaceutic...
Equities analysts expect that Achillion Pharmaceuticals, Inc. will post earnings of per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Achillio...
Bad Marienberg - +++ ACHTUNG +++ Kurseinbruch bei Achillion Pharmaceuticals-Aktie! - Aktiennews Achillion Pharmaceuticals-Aktienanalyse des Analysten Brian Skorney von Robert W. Baird: Der Aktienku...
Brokerages forecast that Achillion Pharmaceuticals, Inc. will post earnings per share for the current quarter, according to Zacks . Zero analysts have made estimates for Achillion Pharmaceuticals'...
Edison Investment Research - Pharmaceutical & healthcare - Achillion Pharmaceuticals: Edison Investment Research is terminating coverage on Achillion Pharmaceuticals (ACHN). Please note you should no ...
Brokerages expect that Achillion Pharmaceuticals, Inc. will post earnings of per share for the current quarter, according to Zacks Investment Research . Zero analysts have provided estimates for Achil...
The purpose of this study is to determine the safety and antiviral HBV activity of ACH-126,443 (beta-L-Fd4C) in the treatment of Subjects of Previous Achillion-Sponsored Phase 1 and 2 Stud...
HIV-1 infected patients receiving long-term therapy with lamivudine or emtricitabine (nucleoside reverse transcriptase inhibitors [NRTIs]) are at risk for the development of a mutation at ...
Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company’s discovery and development teams have advanced mult...
Achillion is a privately held pharmaceutical company focused on the discovery, development and commercialization of innovative small molecule drugs that combat drug resistance in infectious diseases, ...
We have published hundreds of Achillion news stories on BioPortfolio along with dozens of Achillion Clinical Trials and PubMed Articles about Achillion for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Achillion Companies in our database. You can also find out about relevant Achillion Drugs and Medications on this site too.
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...